Go Pro
Leerink Partners

Leerink Partners Analyst Recommendations & Stock Picks

View the latest stock recommendations issued by analysts at Leerink Partners. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Leerink Partners' equity research team. MarketBeat is not affiliated with or endorsed by Leerink Partners.

Average Return
00.00% 12-Month ROI
Total Ratings
393 Last 12 Months
Buy Ratings
260 Last 12 Months
Sell Ratings
3 Last 12 Months
Companies Covered
219 Last 12 Months
MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetails
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$46.75
+1.6%
7/30/2026Set Price Target$60.00View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 7/30/2026
Humana Inc. stock logo
HUM
Humana
$364.54
-0.6%
7/30/2026 Upgrade$513.00Market PerformOutperformView details for Leerink Partners rating of Humana (NYSE:HUM) on 7/30/2026
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$0.17
-4.9%
7/28/2026Upgrade$1.00Market PerformOutperformView details for Leerink Partners rating of Gossamer Bio (NASDAQ:GOSS) on 7/28/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$86.17
-0.9%
7/24/2026Upgrade$87.00 ➝ $101.00Market PerformOutperformView details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 7/24/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$577.11
-0.2%
7/23/2026 Set Price Target$620.00View details for Leerink Partners rating of Medpace (NASDAQ:MEDP) on 7/23/2026
Progyny, Inc. stock logo
PGNY
Progyny
$31.13
-1.1%
7/22/2026Set Price Target$38.00View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 7/22/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$130.21
-0.8%
7/21/2026Downgrade$146.00 ➝ $127.00OutperformMarket PerformView details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 7/21/2026
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$7.07
-1.7%
7/20/2026Initiated Coverage$16.00OutperformView details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 7/20/2026
Elevance Health, Inc. stock logo
ELV
Elevance Health
$375.44
-0.3%
7/17/2026Boost Price Target$364.00 ➝ $395.00Market PerformView details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 7/17/2026
Illumina, Inc. stock logo
ILMN
Illumina
$205.10
+0.0%
7/17/2026Boost Price Target$175.00 ➝ $210.00OutperformView details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 7/17/2026
10x Genomics stock logo
TXG
10x Genomics
$47.27
-4.4%
7/17/2026Boost Price Target$23.00 ➝ $40.00Market PerformView details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 7/17/2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$353.33
+0.1%
7/17/2026Lower Price Target$573.00 ➝ $454.00OutperformView details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 7/17/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$91.55
+0.2%
7/16/2026Set Price Target$110.00View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 7/16/2026
KARD
Kardigan
$20.74
+1.3%
7/13/2026Initiated Coverage$37.00OutperformView details for Leerink Partners rating of Kardigan (NASDAQ:KARD) on 7/13/2026
NGEN
NervGen Pharma
$1.62
+1.3%
7/13/2026Initiated Coverage$10.00OutperformView details for Leerink Partners rating of NervGen Pharma (NASDAQ:NGEN) on 7/13/2026
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$3.85
7/13/2026Initiated Coverage$9.00OutperformView details for Leerink Partners rating of Whitehawk Therapeutics (NASDAQ:WHWK) on 7/13/2026
Bruker Corporation stock logo
BRKR
Bruker
$62.84
-2.3%
7/7/2026Boost Price Target$60.00 ➝ $70.00OutperformView details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 7/7/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$18.25
-5.9%
7/6/2026Initiated Coverage$38.00OutperformView details for Leerink Partners rating of Avalo Therapeutics (NASDAQ:AVTX) on 7/6/2026
Parabilis Medicines, Inc. stock logo
PBLS
Parabilis Medicines
$33.98
+5.3%
7/6/2026Initiated Coverage$40.00OutperformView details for Leerink Partners rating of Parabilis Medicines (NASDAQ:PBLS) on 7/6/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$2.65
-7.7%
7/2/2026Lower Price Target$9.00 ➝ $7.00OutperformView details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 7/2/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$18.44
-2.9%
7/1/2026Boost Price Target$24.00 ➝ $29.00OutperformView details for Leerink Partners rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 7/1/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$124.92
+0.5%
6/30/2026Boost Price Target$140.00 ➝ $148.00OutperformView details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 6/30/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$72.09
+0.1%
6/25/2026Set Price Target$73.00View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,149.28
-0.5%
6/25/2026Boost Price Target$1,119.00 ➝ $1,232.00OutperformView details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 6/25/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$51.77
-2.8%
6/25/2026Boost Price Target$122.00 ➝ $129.00OutperformView details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/25/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$5.13
-8.9%
6/25/2026Lower Price Target$25.00 ➝ $24.00OutperformView details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 6/25/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$72.09
+0.1%
6/25/2026DowngradeStrong-BuyHoldView details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026
Quince Therapeutics, Inc. stock logo
QNCX
Quince Therapeutics
$23.39
+1.6%
6/24/2026Initiated Coverage$80.00OutperformView details for Leerink Partners rating of Quince Therapeutics (NASDAQ:QNCX) on 6/24/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$40.98
-4.2%
6/24/2026Initiated Coverage$52.00OutperformView details for Leerink Partners rating of Rapport Therapeutics (NASDAQ:RAPP) on 6/24/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$9.69
-4.2%
6/22/2026Boost Price Target$17.00 ➝ $18.00OutperformView details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 6/22/2026
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
$43.52
-2.2%
6/22/2026Set Price Target$30.00 ➝ $52.00OutperformView details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 6/22/2026
Altimmune, Inc. stock logo
ALT
Altimmune
$2.84
-4.7%
6/22/2026Initiated Coverage$10.00OutperformView details for Leerink Partners rating of Altimmune (NASDAQ:ALT) on 6/22/2026
uniQure N.V. stock logo
QURE
uniQure
$43.63
+3.4%
6/18/2026Boost Price Target$36.00 ➝ $70.00OutperformView details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 6/18/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$84.65
-3.1%
6/17/2026Boost Price Target$61.00 ➝ $72.00Market PerformView details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/17/2026
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$51.77
-2.8%
6/17/2026Boost Price Target$114.00 ➝ $122.00OutperformView details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/17/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$414.82
-1.6%
6/17/2026Boost Price Target$400.00 ➝ $462.00OutperformView details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 6/17/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$38.43
-6.5%
6/16/2026 Set Price Target$52.00View details for Leerink Partners rating of Edgewise Therapeutics (NASDAQ:EWTX) on 6/16/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$3.57
+0.3%
6/15/2026Boost Price Target$7.00 ➝ $12.00OutperformView details for Leerink Partners rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/15/2026
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$18.62
+3.4%
6/11/2026Downgrade$31.00 ➝ $29.00OutperformMarket PerformView details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 6/11/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$27.18
-1.4%
6/8/2026Boost Price Target$55.00 ➝ $69.00OutperformView details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 6/8/2026
The end may be near for these iconic stocks (Ad)

Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel

Watch Marc Chaikin's free presentation and get his full buy-and-sell list today
Stryker Corporation stock logo
SYK
Stryker
$326.41
-6.2%
6/5/2026Lower Price Target$410.00 ➝ $407.00OutperformView details for Leerink Partners rating of Stryker (NYSE:SYK) on 6/5/2026
Nanobiotix S.A. - Sponsored ADR stock logo
NBTX
Nanobiotix
$38.38
-4.4%
6/4/2026Boost Price Target$37.00 ➝ $46.00OutperformView details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 6/4/2026
Absci Corporation stock logo
ABSI
Absci
$7.78
+1.8%
6/4/2026Initiated Coverage$12.00OutperformView details for Leerink Partners rating of Absci (NASDAQ:ABSI) on 6/4/2026
Medtronic PLC stock logo
MDT
Medtronic
$85.64
-0.1%
6/4/2026Lower Price Target$117.00 ➝ $104.00OutperformView details for Leerink Partners rating of Medtronic (NYSE:MDT) on 6/4/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$123.96
6/3/2026Set Price Target$165.00View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 6/3/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$8.66
-2.7%
6/3/2026Boost Price Target$20.00 ➝ $21.00OutperformView details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 6/3/2026
Celcuity, Inc. stock logo
CELC
Celcuity
$86.38
-1.4%
6/2/2026Set Price Target$155.00View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 6/2/2026
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$3.58
-3.8%
6/2/2026Downgrade$4.00OutperformMarket PerformView details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 6/2/2026
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$3.98
-0.5%
6/2/2026Initiated Coverage$12.00OutperformView details for Leerink Partners rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 6/2/2026
Icon Plc stock logo
ICLR
Icon
$163.30
-1.3%
5/28/2026Set Price Target$145.00View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/28/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$46.75
+1.6%
5/28/2026Lower Price Target$87.00 ➝ $74.00OutperformView details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 5/28/2026
Equillium, Inc. stock logo
EQ
Equillium
$2.20
-5.2%
5/28/2026Upgrade$1.00 ➝ $6.00Market PerformOutperformView details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 5/28/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,149.28
-0.5%
5/26/2026Set Price Target$1,119.00View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 5/26/2026
Seaport Therapeutics, Inc. stock logo
SPTX
Seaport Therapeutics
$20.46
+0.7%
5/26/2026Initiated Coverage$35.00OutperformView details for Leerink Partners rating of Seaport Therapeutics (NASDAQ:SPTX) on 5/26/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$91.55
+0.2%
5/22/2026Set Price Target$80.00View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/22/2026
Encompass Health Corporation stock logo
EHC
Encompass Health
$111.27
+0.3%
5/22/2026Set Price Target$152.00View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 5/22/2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$33.91
-1.8%
5/21/2026Set Price Target$42.00View details for Leerink Partners rating of Roivant Sciences (NASDAQ:ROIV) on 5/21/2026
Compugen Ltd. stock logo
CGEN
Compugen
$2.35
+0.4%
5/21/2026 Lower Price Target$13.00 ➝ $5.00OutperformView details for Leerink Partners rating of Compugen (NASDAQ:CGEN) on 5/21/2026
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
$3.71
-3.4%
5/21/2026Initiated Coverage$10.00OutperformView details for Leerink Partners rating of Opus Genetics (NASDAQ:IRD) on 5/21/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$762.63
+3.3%
5/18/2026Reiterated Rating$792.00 ➝ $641.00OutperformMarket PerformView details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/18/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$316.01
-1.9%
5/15/2026 Boost Price Target$364.00 ➝ $367.00OutperformView details for Leerink Partners rating of BeOne Medicines (NASDAQ:ONC) on 5/15/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$53.36
-3.1%
5/15/2026Set Price Target$90.00View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 5/15/2026
Immunome, Inc. stock logo
IMNM
Immunome
$22.76
-1.4%
5/15/2026Lower Price Target$37.00 ➝ $33.00OutperformView details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 5/15/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$24.17
-2.6%
5/15/2026 Set Price Target$38.00 ➝ $43.00OutperformView details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 5/15/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$11.35
-1.0%
5/15/2026Initiated CoverageOutperformView details for Leerink Partners rating of Avidity Biosciences (NASDAQ:RNA) on 5/15/2026
Doximity, Inc. stock logo
DOCS
Doximity
$20.95
-1.4%
5/14/2026Lower Price Target$31.00 ➝ $25.00OutperformView details for Leerink Partners rating of Doximity (NYSE:DOCS) on 5/14/2026
AirSculpt Technologies, Inc. stock logo
AIRS
AirSculpt Technologies
$4.81
-0.8%
5/14/2026 Set Price Target$4.50View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2026
Anthem, Inc. stock logo
ANTX
Anthem
$5.35
+0.4%
5/14/2026Upgrade$9.00Market PerformOutperformView details for Leerink Partners rating of Anthem (NASDAQ:ANTX) on 5/14/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$27.18
-1.4%
5/14/2026Boost Price Target$28.00 ➝ $55.00OutperformView details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 5/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$256.52
+0.3%
5/13/2026Upgrade$265.00Market PerformOutperformView details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2026
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$7.01
-1.4%
5/12/2026 Set Price Target$17.00View details for Leerink Partners rating of Aura Biosciences (NASDAQ:AURA) on 5/12/2026
ALMR
Alamar Biosciences
$25.36
+1.2%
5/12/2026Initiated Coverage$35.00OutperformView details for Leerink Partners rating of Alamar Biosciences (NASDAQ:ALMR) on 5/12/2026
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
$16.94
-0.6%
5/12/2026Initiated Coverage$36.00OutperformView details for Leerink Partners rating of Kailera Therapeutics (NASDAQ:KLRA) on 5/12/2026
enGene Holdings Inc. stock logo
ENGN
enGene
$1.79
+1.7%
5/8/2026 Downgrade$2.00OutperformMarket PerformView details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 5/8/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$130.21
-0.8%
5/8/2026 Lower Price Target$148.00 ➝ $146.00View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 5/8/2026
Insulet Corporation stock logo
PODD
Insulet
$165.35
-0.2%
5/7/2026 Lower Price Target$360.00 ➝ $247.00View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 5/7/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$91.55
+0.2%
5/5/2026Upgrade$70.00Market PerformOutperformView details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/5/2026
Icon Plc stock logo
ICLR
Icon
$163.30
-1.3%
5/4/2026Set Price Target$125.00View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/4/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$96.64
-1.2%
4/30/2026Set Price Target$120.00View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 4/30/2026
Align Technology, Inc. stock logo
ALGN
Align Technology
$169.16
-2.5%
4/30/2026 Boost Price Target$225.00 ➝ $230.00View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 4/30/2026
Humana Inc. stock logo
HUM
Humana
$364.54
-0.6%
4/30/2026 Boost Price Target$185.00 ➝ $255.00Market PerformView details for Leerink Partners rating of Humana (NYSE:HUM) on 4/30/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$15.29
-3.7%
4/29/2026Upgrade$12.00 ➝ $25.00Market PerformOutperformView details for Leerink Partners rating of NeoGenomics (NASDAQ:NEO) on 4/29/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$53.36
-3.1%
4/28/2026Boost Price Target$66.00 ➝ $85.00OutperformView details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/28/2026
CorMedix Inc stock logo
CRMD
CorMedix
$7.53
+0.5%
4/28/2026Boost Price Target$13.00 ➝ $14.00OutperformView details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 4/28/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$10.68
-3.7%
4/27/2026 Set Price Target$35.00View details for Leerink Partners rating of Intellia Therapeutics (NASDAQ:NTLA) on 4/27/2026
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$403.44
+1.9%
4/27/2026 Lower Price Target$573.00 ➝ $500.00OutperformView details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 4/27/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,149.28
-0.5%
4/27/2026 Lower Price Target$1,296.00 ➝ $1,058.00OutperformView details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 4/27/2026
TRAX
First Tracks Biotherapeutics
$44.04
-7.8%
4/24/2026Initiated Coverage$46.00OutperformView details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 4/24/2026
Elevance Health, Inc. stock logo
ELV
Elevance Health
$375.44
-0.3%
4/23/2026 Set Price Target$364.00View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 4/23/2026
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
$12.83
-10.1%
4/22/2026Lower Price Target$25.00 ➝ $24.00OutperformView details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 4/22/2026
Porter flew 3,300 miles to investigate this system (Ad)

Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel

Watch the full investigation and decide for yourself
Definium Therapeutics, Inc. stock logo
DFTX
Definium Therapeutics
$43.52
-2.2%
4/22/2026Boost Price Target$23.00 ➝ $30.00OutperformView details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 4/22/2026
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$23.02
-5.5%
4/22/2026Lower Price Target$40.00 ➝ $35.00OutperformView details for Leerink Partners rating of Denali Therapeutics (NASDAQ:DNLI) on 4/22/2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$353.33
+0.1%
4/22/2026Lower Price Target$622.00 ➝ $573.00OutperformView details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 4/22/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$252.86
-2.1%
4/22/2026Boost Price Target$215.00 ➝ $225.00OutperformView details for Leerink Partners rating of Jazz Pharmaceuticals (NASDAQ:JAZZ) on 4/22/2026
Veradermics, Incorporated stock logo
MANE
Veradermics
$105.05
+0.4%
4/22/2026Boost Price Target$75.00 ➝ $90.00OutperformView details for Leerink Partners rating of Veradermics (NYSE:MANE) on 4/22/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$166.80
-10.1%
4/22/2026Boost Price Target$160.00 ➝ $170.00OutperformView details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 4/22/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$414.82
-1.6%
4/22/2026Boost Price Target$345.00 ➝ $400.00OutperformView details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 4/22/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$105.99
+0.4%
4/21/2026 Lower Price Target$119.00 ➝ $106.00Market PerformView details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 4/21/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$28.18
-0.3%
4/20/2026 Set Price Target$47.00View details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 4/20/2026
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
$27.24
-5.5%
4/20/2026 Initiated Coverage$50.00OutperformView details for Leerink Partners rating of Sensei Biotherapeutics (NASDAQ:FTH) on 4/20/2026

MarketBeat's community ratings are surveys of what our community members think about Leerink Partners and other research firms in the last 90 days. Vote "Outperform" if you believe Leerink Partners's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Leerink Partners's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.
COMMUNITY RATINGS
0.0out of 5 (last 90 days)
0 of 5 stars
OUTPERFORM VOTES
0 Believe will outperform the market
UNDERPERFORM VOTES
0 Believe will underperform the market

Leerink Partners' equity research team has issued ratings on 218 companies across 5 sectors over the past 12 months, covered by 20 analysts. The Leerink Partners analysts below are listed by number of ratings issued in the last year.

Leerink Partners Stock Coverage by Sector

Leerink Partners concentrates its research most heavily in Healthcare (97.7%), Industrials (0.5%) and Technology (0.5%). The chart below shows how Leerink Partners' 219 rated companies are distributed across all 5 sectors it covers.

Leerink Partners - Frequently Asked Questions

Leerink Partners' analysts currently have buy-equivalent ratings on 167 companies. Recent upgrades to buy include Humana, Gossamer Bio, Edwards Lifesciences, Equillium and Anthem.

Leerink Partners' highest-rated analysts by MarketBeat's accuracy score include Faisal Khurshid, Andrew Berens and Joseph Schwartz. Rankings are based on historical rating accuracy and price target precision over the past 12 months. MarketBeat tracks 20 analysts at Leerink Partners.

Leerink Partners has the deepest coverage in Healthcare (97.7% of rated companies), Technology (0.5% of rated companies), Industrials (0.5% of rated companies), Finance (0.5% of rated companies) and Consumer Discretionary (0.5% of rated companies).

Leerink Partners issued 393 ratings over the last 12 months across 219 companies — an average of roughly 33 rating actions per month. These include boost price target, downgrade, initiated coverage, lower price target, reiterated rating, set price target and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Leerink Partners analyst actions.

A buy rating indicates the analyst expects the stock to outperform the market over the next 12 months. A hold suggests the stock will perform in line with the market. A sell rating indicates expected underperformance. Leerink Partners uses Outperform, Market Perform, and Underperform as their equivalents.